Clinical trial
Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB…
NCT00066768 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00066768 |
|---|---|
| Title | Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer |
| Official title | A Pilot Study of Low Dose Suramin as Modulator of Docetaxel and Gemcitabine in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | suramin, docetaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 24 |
| Start date | Jul 1, 2003 |
| Primary completion | Mar 1, 2008 |
| First posted | Aug 7, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: